Lördag 5 April | 00:21:20 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-12 10:00 Bokslutskommuniké 2025
2025-11-06 10:00 Kvartalsrapport 2025-Q3
2025-07-22 10:00 Kvartalsrapport 2025-Q2
2025-05-15 N/A X-dag ordinarie utdelning DVYSR 0.00 SEK
2025-05-14 N/A Årsstämma
2025-04-29 10:00 Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2024-05-14 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-20 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2023-05-10 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Devyser Diagnostics utvecklar, tillverkar och säljer genetiska tester till laboratorier globalt. Produkterna används för DNA-tester inom onkologi, transplantation och ärftliga sjukdomar för att möjliggöra skräddarsydd cancerbehandling, diagnostik av ett stort antal genetiska sjukdomar och uppföljning av transplanterade patienter. Bolaget har sitt huvudkontor i Hägersten.
2025-03-24 10:00:00

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Devyser Genomic Laboratories, Roswell, Georgia, based on the results of a recent on-site inspection as part of the CAP’s Accreditation programs. Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved patient outcomes.

The facility’s director, Daniel H. Farkas PhD, HCLD, was advised of this global recognition and congratulated on the excellence of the services provided. Devyser Genomic Laboratories is one of more than 8,000 CAP-accredited facilities worldwide. 

“Achieving CAP accreditation is a huge achievement for our US based lab and a testament to the high standards we uphold in genetic testing. The accreditation is as per our expected timeline and enables us to accelerate the upcoming reimbursement and launch activities of our post-transplantation test for solid organs, TransplantTrace cfDNA” says Devyser’s Chief Commercial Officer, Theis Kipling. 

During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. These reviews help verify activities and reflect the most recent best practices. 

With over 23,000 laboratory participants, in addition to accreditation, the CAP offers proficiency testing/external quality assessment (PT/EQA) programs, quality improvement tools, and protocols and guidelines to ensure excellence in all areas across the laboratory. Built on a foundation of pathologist expertise, the College of American Pathologists (CAP) partners with laboratories worldwide to elevate the quality of laboratory medicine with best-in-class solutions designed to drive operational excellence, achieve diagnostic confidence, and ensure the best patient care.